In the BioHarmony Drug Report Database
Picato (ingenol mebutate) is a small molecule pharmaceutical. Ingenol mebutate was first approved as Picato on 2012-01-23. It is used to treat actinic keratosis in the USA. The pharmaceutical is active against protein kinase C delta type. In addition, it is known to target protein kinase C epsilon type, protein kinase C alpha type, protein kinase C gamma type, and protein kinase C beta type. Picato’s patents are valid until 2033-05-15 (FDA).
Image (chem structure or protein)